Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.

作者信息

Inzucchi Silvio E

机构信息

Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06520-8020, USA.

出版信息

Endocrinol Metab Clin North Am. 2007 Dec;36 Suppl 2 Incretin:2-17.

DOI:

PMID:18405144

Abstract

摘要

相似文献

[1]

Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.

Endocrinol Metab Clin North Am. 2007-12

[2]

Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.

J Am Acad Nurse Pract. 2008-11

[3]

Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?

Diabetes Care. 2008-2

[4]

Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.

Diabetes Educ. 2008

[5]

Which oral agent to use when metformin is no longer effective?

QJM. 2011-3

[6]

Diabetes under control: Understanding oral antidiabetic agents.

Am J Nurs. 2010-2

[7]

[Pharmacologic treatment of diabetes].

Perspect Infirm. 2006

[8]

Clinical decisions. Management of type 2 diabetes.

N Engl J Med. 2008-1-17

[9]

Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.

Health News. 2005-2

[10]

The backbone of oral glucose-lowering therapy: time for a paradigm shift?

Fundam Clin Pharmacol. 2009-3-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献